Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Progression of diabetic retinopathy in patients treated with 0.2 μg/day
Raymond Iezzi, MD, MS
Updates from the Field
2017
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Updates from the Field
2022
Endolaserless Vitrectomy with Intravitreal Aflibercept
Dennis M. Marcus, MD
Updates from the Field
2017

Category: AMD-Neovascular

See more